Overview

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Status:
Completed
Trial end date:
2013-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).
Phase:
Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Pomalidomide
Prednisone
Thalidomide